Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

Zikani Therapeutics Inc. hired Vijay Modur as chief scientific and medical officer. He was global project head in rare disease clinical development at the Genzyme unit of Sanofi (Euronext:SAN; NASDAQ:SNY). Zikani is developing ribosome modulating agents to treat rare, nonsense mutation-driven diseases.

Growth factor modulation